Examining 3 major risk factors of AMD

Video

Joshua Mali, MD, discusses the three major risk factors for developing age-related macular degeneration (AMD).

Joshua Mali, MD, retina medical director, Macular Degeneration Association; vitreoretinal surgeon at The Eye Associates (Sarasota, FL); founder, CEO, Mali Enterprises, discusses the three major risk factors for developing age-related macular degeneration (AMD).

See more AMD Awareness content here, here, and here.

Recent Videos
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Related Content
A person in a suit sits at a laptop. A US Food and Drug Administration logo and approval badge are superimposed over the image. Image credit: ©Nirusmee – stock.adobe.com

US FDA approves continuous delivery ranibizumab treatment (Susvimo, Genentech) for diabetic macular oedema

Martin David Harp
February 4th 2025
Article

Previously, Susvimo was called the Port Delivery System with ranibizumab in the United States

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A gloved hand holding a syringe, superimposed over the European Union flag. Image credit: ©Savvapanf Photo – stock.adobe.com

European Medicines Agency CHMP adopts positive opinions for two aflibercept biosimilars

Hattie Hayes
February 3rd 2025
Article

Pavblu and Skojoy, both from Amgen, are indicated for the treatment of neovascular age-related macular degeneration

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

An elderly woman undergoes an eye exam. Image credit: ©kasto – stock.adobe.com

SeaBeLife announces preclinical efficacy results for SBL03 topical ophthalmic gel

Hattie Hayes
January 30th 2025
Article

The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections

Apellis Pharmaceuticals receives Australian approval of pegcetacoplan (Syfovre) for treatment of geographic atrophy

Apellis Pharmaceuticals receives Australian approval of pegcetacoplan (Syfovre) for treatment of geographic atrophy

Martin David Harp
January 28th 2025
Article

The approval of Syfovre makes it the first and only approved treatment for GA in Australia.

© 2025 MJH Life Sciences

All rights reserved.